Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE37.8300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots15.1400/ 2
- Ask / Lots50.0000/ 1
- Open / Previous Close0.0000 / 37.8300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 2362 | 38.335 |
| 09:34 ET | 100 | 38.32 |
| 09:36 ET | 300 | 37.98 |
| 09:41 ET | 100 | 37.81 |
| 09:45 ET | 1563 | 37.82 |
| 09:50 ET | 100 | 37.82 |
| 09:54 ET | 100 | 37.88 |
| 09:56 ET | 1020 | 38.12 |
| 09:57 ET | 300 | 38.25 |
| 10:03 ET | 200 | 38.22 |
| 10:06 ET | 100 | 38.205 |
| 10:08 ET | 3312 | 38.36 |
| 10:15 ET | 100 | 38.33 |
| 10:21 ET | 100 | 38.22 |
| 10:26 ET | 260 | 38.3 |
| 10:28 ET | 8443 | 38.26 |
| 10:30 ET | 600 | 38.145 |
| 10:32 ET | 200 | 38.13 |
| 10:33 ET | 100 | 38.07 |
| 10:37 ET | 750 | 38.03 |
| 10:39 ET | 900 | 38.0009 |
| 10:42 ET | 700 | 38.04 |
| 10:46 ET | 369 | 37.98 |
| 10:48 ET | 100 | 37.98 |
| 10:50 ET | 1383 | 38.16 |
| 10:51 ET | 100 | 38.14 |
| 10:53 ET | 300 | 38.07 |
| 10:55 ET | 546 | 38.15 |
| 10:57 ET | 1300 | 38.11 |
| 11:06 ET | 100 | 37.99 |
| 11:08 ET | 211 | 38.02 |
| 11:11 ET | 700 | 38.05 |
| 11:13 ET | 200 | 38.05 |
| 11:26 ET | 200 | 37.92 |
| 11:29 ET | 808 | 37.97 |
| 11:31 ET | 300 | 37.915 |
| 11:33 ET | 100 | 37.955 |
| 11:38 ET | 200 | 37.85 |
| 11:40 ET | 1009 | 37.8 |
| 11:42 ET | 891 | 37.81 |
| 11:45 ET | 300 | 37.69 |
| 11:51 ET | 100 | 37.68 |
| 11:54 ET | 106 | 37.71 |
| 11:56 ET | 500 | 37.74 |
| 12:00 ET | 246 | 37.73 |
| 12:02 ET | 839 | 37.65 |
| 12:03 ET | 100 | 37.62 |
| 12:05 ET | 100 | 37.58 |
| 12:09 ET | 571 | 37.69 |
| 12:12 ET | 600 | 37.65 |
| 12:14 ET | 960 | 37.67 |
| 12:16 ET | 700 | 37.71 |
| 12:18 ET | 421 | 37.67 |
| 12:20 ET | 200 | 37.71 |
| 12:21 ET | 100 | 37.71 |
| 12:23 ET | 200 | 37.67 |
| 12:25 ET | 5200 | 37.67 |
| 12:27 ET | 500 | 37.59 |
| 12:32 ET | 600 | 37.59 |
| 12:34 ET | 1003 | 37.5581 |
| 12:36 ET | 200 | 37.44 |
| 12:38 ET | 200 | 37.41 |
| 12:39 ET | 3687 | 37.29 |
| 12:41 ET | 1762 | 37.36 |
| 12:43 ET | 400 | 37.35 |
| 12:52 ET | 100 | 37.33 |
| 12:54 ET | 100 | 37.385 |
| 12:57 ET | 914 | 37.315 |
| 12:59 ET | 448 | 37.3 |
| 01:01 ET | 200 | 37.29 |
| 01:03 ET | 2100 | 37.26 |
| 01:06 ET | 200 | 37.305 |
| 01:08 ET | 200 | 37.36 |
| 01:14 ET | 100 | 37.31 |
| 01:17 ET | 408 | 37.3 |
| 01:21 ET | 700 | 37.24 |
| 01:24 ET | 507 | 37.2639 |
| 01:26 ET | 200 | 37.28 |
| 01:28 ET | 400 | 37.34 |
| 01:30 ET | 554 | 37.36 |
| 01:32 ET | 500 | 37.27 |
| 01:35 ET | 20518 | 37.45 |
| 01:37 ET | 348 | 37.51 |
| 01:44 ET | 41213 | 37.52 |
| 01:48 ET | 500 | 37.47 |
| 01:50 ET | 100 | 37.43 |
| 01:51 ET | 500 | 37.54 |
| 01:53 ET | 300 | 37.49 |
| 01:55 ET | 300 | 37.47 |
| 01:57 ET | 2803 | 37.46 |
| 02:00 ET | 902 | 37.55 |
| 02:02 ET | 560 | 37.745 |
| 02:04 ET | 400 | 37.71 |
| 02:08 ET | 700 | 37.72 |
| 02:09 ET | 133 | 37.66 |
| 02:13 ET | 600 | 37.73 |
| 02:18 ET | 100 | 37.74 |
| 02:20 ET | 600 | 37.79 |
| 02:22 ET | 600 | 37.89 |
| 02:24 ET | 752 | 37.83 |
| 02:27 ET | 342 | 37.86 |
| 02:29 ET | 200 | 37.82 |
| 02:31 ET | 617 | 37.815 |
| 02:33 ET | 100 | 37.77 |
| 02:36 ET | 945 | 37.805 |
| 02:38 ET | 2000 | 37.94 |
| 02:40 ET | 100 | 37.935 |
| 02:42 ET | 300 | 37.97 |
| 02:44 ET | 2534 | 37.955 |
| 02:45 ET | 200 | 37.945 |
| 02:47 ET | 200 | 37.93 |
| 02:51 ET | 500 | 37.88 |
| 02:56 ET | 343 | 37.86 |
| 02:58 ET | 300 | 37.87 |
| 03:00 ET | 300 | 37.825 |
| 03:02 ET | 542 | 37.77 |
| 03:05 ET | 1549 | 37.83 |
| 03:07 ET | 300 | 37.8 |
| 03:09 ET | 500 | 37.79 |
| 03:12 ET | 700 | 37.795 |
| 03:16 ET | 1303 | 37.83 |
| 03:18 ET | 2765 | 37.87 |
| 03:20 ET | 100 | 37.82 |
| 03:21 ET | 600 | 37.82 |
| 03:25 ET | 600 | 37.81 |
| 03:27 ET | 100 | 37.82 |
| 03:30 ET | 400 | 37.79 |
| 03:32 ET | 2300 | 37.68 |
| 03:36 ET | 2151 | 37.565 |
| 03:38 ET | 1473 | 37.54 |
| 03:39 ET | 3532 | 37.555 |
| 03:41 ET | 4755 | 37.65 |
| 03:43 ET | 500 | 37.71 |
| 03:45 ET | 300 | 37.705 |
| 03:48 ET | 5944 | 37.64 |
| 03:50 ET | 600 | 37.67 |
| 03:52 ET | 2095 | 37.69 |
| 03:54 ET | 2900 | 37.67 |
| 03:56 ET | 3923 | 37.8047 |
| 03:57 ET | 4440 | 37.8 |
| 03:59 ET | 35368 | 37.83 |
Jun 5, 2024
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
4:01PM ET on Wednesday Jun 05, 2024 by Dow Jones
May 28, 2024
May 10, 2024
DJ Xenon Pharmaceuticals Is Maintained at Buy by Needham, from 6:12PM ET on Friday May 10, 2024 by Dow Jones
6:12PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Buy by Citigroup, from 5:48PM ET on Friday May 10, 2024 by Dow Jones
5:48PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush, from 9:30AM ET on Friday May 10, 2024 by Dow Jones
9:30AM ET on Friday May 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.9B | -13.9x | --- |
Janux Therapeutics Inc | 2.8B | -34.8x | --- |
Apogee Therapeutics Inc | 2.7B | -20.6x | --- |
Biohaven Ltd | 3.1B | -4.9x | --- |
SpringWorks Therapeutics Inc | 3.1B | -7.7x | --- |
Dyne Therapeutics Inc | 3.1B | -8.2x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.22 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -13.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
